Effect of Elexacaftor/Tezacaftor/Ivacaftor on Acquisition and Chronic Infection at a Single Pediatric Cystic Fibrosis Care Center

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2024 Apr 10

PMID 38596420

Authors

Stephanie Duehlmeyer

Elizabeth Claire Elson

Christopher M Oermann

Affiliations

Soon will be listed here.

Abstract

Objectives: As cystic fibrosis (CF) lung disease progresses, the airways become infected with opportunistic pathogens, such as (PA). In October 2019, the US Food and Drug Administration approved elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective modulator therapy (HEMT), for individuals 12 years and older with 1 copy of the F508del cystic fibrosis transmembrane conductance regulator () mutation. ETI increases the amount of and function of CFTR in the respiratory epithelium, improving mucociliary clearance and reducing static airway mucus, a major trigger for chronic infection and inflammation.

Methods: A retrospective analysis of inhaled tobramycin (iTOB) prescriptions between January 1, 2016, and December 31, 2021, was performed. This captured data before and after ETI approval at Children's Mercy Kansas City (CMKC). The number of individuals with new PA acquisition and individuals considered -chronically infected was analyzed.

Results: The number of eradication prescriptions declined in 2020 and 2021, with 15 (7%) and 12 (5%) -individuals prescribed therapy for those years, respectively. A similar pattern was observed for -prescriptions for chronic infection. A reduction was seen in 2020 and 2021, with 28 (13%) and 20 (9%) individuals -prescribed therapy for the respective years.

Conclusions: The CMKC experienced a decrease in the number of courses of iTOB prescribed during the last 6 years. The reasons for this are likely multifactorial and may include the implementation of standardized PA surveillance and eradication protocols, the effect of HEMT on mucociliary clearance and airway microbiology, and the poorly understood effects of the SARS-CoV-2 pandemic on the epidemiology of respiratory infections.

References

Mall M, Mayer-Hamblett N, Rowe S . Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med. 2019; 201(10):1193-1208. PMC: 7233349. DOI: 10.1164/rccm.201910-1943SO. View

Zampoli M, Pillay K, Carrara H, Zar H, Morrow B . Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis. J Cyst Fibros. 2016; 15(5):605-10. DOI: 10.1016/j.jcf.2016.01.001. View

Lee T, Brownlee K, Conway S, Denton M, Littlewood J . Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2004; 2(1):29-34. DOI: 10.1016/S1569-1993(02)00141-8. View

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

Yeoh D, Foley D, Minney-Smith C, Martin A, Mace A, Sikazwe C . Impact of Coronavirus Disease 2019 Public Health Measures on Detections of Influenza and Respiratory Syncytial Virus in Children During the 2020 Australian Winter. Clin Infect Dis. 2020; 72(12):2199-2202. PMC: 7543326. DOI: 10.1093/cid/ciaa1475. View

Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K . Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 1999; 28(5):321-8. DOI: 10.1002/(sici)1099-0496(199911)28:5<321::aid-ppul3>3.0.co;2-v. View

Kuitunen I, Artama M, Makela L, Backman K, Heiskanen-Kosma T, Renko M . Effect of Social Distancing Due to the COVID-19 Pandemic on the Incidence of Viral Respiratory Tract Infections in Children in Finland During Early 2020. Pediatr Infect Dis J. 2020; 39(12):e423-e427. DOI: 10.1097/INF.0000000000002845. View

Seidler D, Griffin M, Nymon A, Koeppen K, Ashare A . Throat Swabs and Sputum Culture as Predictors of P. aeruginosa or S. aureus Lung Colonization in Adult Cystic Fibrosis Patients. PLoS One. 2016; 11(10):e0164232. PMC: 5053402. DOI: 10.1371/journal.pone.0164232. View

Eyns H, Pierard D, De Wachter E, Eeckhout L, Vaes P, Malfroot A . Respiratory Bacterial Culture Sampling in Expectorating and Non-expectorating Patients With Cystic Fibrosis. Front Pediatr. 2019; 6:403. PMC: 6305441. DOI: 10.3389/fped.2018.00403. View

10.

Davies J, Alton E, Bush A . Cystic fibrosis. BMJ. 2007; 335(7632):1255-9. PMC: 2137053. DOI: 10.1136/bmj.39391.713229.AD. View

11.

Tang J, Bialasiewicz S, Dwyer D, Dilcher M, Tellier R, Taylor J . Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. J Med Virol. 2021; 93(7):4099-4101. PMC: 8250511. DOI: 10.1002/jmv.26964. View

12.

Rowe S, Heltshe S, Gonska T, Donaldson S, Borowitz D, Gelfond D . Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014; 190(2):175-84. PMC: 4226057. DOI: 10.1164/rccm.201404-0703OC. View

13.

Heltshe S, Mayer-Hamblett N, Burns J, Khan U, Baines A, Ramsey B . Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2014; 60(5):703-12. PMC: 4342673. DOI: 10.1093/cid/ciu944. View

14.

Esther Jr C, Lin F, Kerr A, Miller M, Gilligan P . Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol. 2013; 49(9):926-31. DOI: 10.1002/ppul.22917. View

15.

Mogayzel Jr P, Naureckas E, Robinson K, Brady C, Guill M, Lahiri T . Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014; 11(10):1640-50. DOI: 10.1513/AnnalsATS.201404-166OC. View

16.

Farrell P, White T, Ren C, Hempstead S, Accurso F, Derichs N . Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017; 181S:S4-S15.e1. DOI: 10.1016/j.jpeds.2016.09.064. View

17.

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View